©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Table 4 Summary of changes from baseline at 3 months, 6 months and 9 months for patients with secondary loss of response
| Marker | 3 months | 6 months | 9 months | |||||||||
| n | Mean change | 95%CI | P value | n | Mean change | 95%CI | P value | n | Mean change | 95%CI | P value | |
| Albumin (g/L) | 41 | +1.44 | 36.79-39.13 | 0.004 | 37 | +1.31 | 36.69-39.36 | 0.019 | 22 | +2.08 | 38.00-41.18 | 0.003 |
| CRP (mg/L) | 41 | -5.1 | -12.2-1.99 | 0.158 | 37 | 2.03 | -5.88-9.95 | 0.606 | 22 | -7.56 | -17.1-1.97 | 0.115 |
| FCP (μg/g) | 28 | -291 | -688.5-91.0 | 0.133 | 19 | -291 | -686.9-104.1 | 0.149 | 8 | -376 | -757.3 to -5.7 | 0.054 |
| HBI | 37 | -0.55 | 1.91-3.49 | 0.221 | 32 | -1.09 | 1.44-3.31 | 0.031 | 18 | -2.62 | 0.68-2.16 | < 0.001 |
- Citation: Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; 16(4): 110273
- URL: https://www.wjgnet.com/2150-5349/full/v16/i4/110273.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i4.110273